1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Delayed Swiss Exchange  -  11:31 2022-08-09 am EDT
92.50 CHF   -3.24%
07/29TRANSCRIPT : Medacta Group SA, H1 2022 Earnings Call, Jul 29, 2022
CI
07/29Medacta Expects to Hit Top End of FY Revenue Guidance After 19% Growth in H1
MT
07/29MEDACTA : 2022 Half-Year Unaudited Top-Line Figures Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta Group announces the results of today's Annual General Meeting

05/19/2022 | 01:02pm EDT

Medacta Group SA / Key word(s): AGMEGM
Medacta Group announces the results of today's Annual General Meeting

19.05.2022 / 19:00


Media Release

Medacta Group announces the results of today's Annual General Meeting

- All proposals of the Board of Directors were approved

- The distribution of CHF 10.7 million or CHF 0.535 per share was approved

- Dr. Alberto Siccardi as Chair of the Board of Directors and all other Board members standing for re-election were confirmed

CASTEL SAN PIETRO, Switzerland, 19 May 2022 ? Medacta Group SA (?Medacta?, SIX:MOVE) today announced that its Shareholders approved all proposals made by the Board of Directors at today's Annual General Meeting (?AGM?).

Today's AGM was held without the physical participation of Shareholders. Accordingly, Shareholders were asked to exercise their voting rights by giving a power of attorney and related instructions to the independent proxy, either by returning the proxy form or by exercising their voting rights online.

The meeting took place at Medacta's headquarters in Castel San Pietro (TI) in the presence of the independent proxy Fulvio Pelli, Medacta's Chairman, Dr. Alberto Siccardi, Medacta's CEO, Francesco Siccardi, and the Secretary of the Board, Donato Cortesi. A total of 18?408?518 shares were represented by the independent proxy, corresponding to approximately 92% of Medacta's share capital.

Shareholders approved the distribution of CHF 10.7 million or CHF 0.535 per share, half of it to be distributed as dividend out of available earnings and half of it to be distributed out of accumulated reserves from capital contribution.

Dr. Alberto Siccardi, Maria Luisa Siccardi Tonolli, Victor Balli, Riccardo Braglia and Philippe Weber were each re-elected as members of the Board of Directors for one-year term of office and Dr. Alberto Siccardi was re-elected as chairman of the Board. Medacta's Shareholders also re-elected Philippe Weber and Riccardo Braglia as members of the Remuneration Committee for a term of one year.

Further proposals by the Board of Directors that were approved at today's AGM included the following:

- The approval of Management Report, the Annual Statutory Financial Statements and the Consolidated Financial Statements for the financial year 2021;

- The approval of Remuneration Report for the financial year 2021;

- The approval of the appropriation of available earnings as of 31 December 2021 of Medacta Group SA for the financial year 2021;

- The discharge of the members of the Board of Directors and the Executive Management;

- The re-election of the independent proxy and the auditors;

- The maximum aggregate compensations of the Board of Directors and the members of the Executive Management.

The minutes of the 2022 AGM will be available in due course at:
https://www.medacta.com/EN/agm.

Contact
Medacta International SA
Gianna La Rana, Head of Investor Relations
Phone: +41 91 696 14 95
investor.relations@medacta.ch


About Medacta
Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.



End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1357185

 
End of News EQS News Service

1357185  19.05.2022 

fncls.ssp?fn=show_t_gif&application_id=1357185&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about MEDACTA GROUP SA
07/29TRANSCRIPT : Medacta Group SA, H1 2022 Earnings Call, Jul 29, 2022
CI
07/29Medacta Expects to Hit Top End of FY Revenue Guidance After 19% Growth in H1
MT
07/29MEDACTA : 2022 Half-Year Unaudited Top-Line Figures Presentation
PU
07/29Medacta Group SA reports 19.0% growth of half-year revenue
EQ
07/29Medacta Group SA Announces Unaudited Revenue Results for the First Half Ended June 30, ..
CI
07/29Medacta Group SA Provides Revenue Guidance for the Year 2022
CI
06/23Medacta Announces First Lumbar Fusion Procedure with NextAR Augmented Reality Surgical ..
EQ
05/24MEDACTA : Company Presentation
PU
05/19Medacta Group announces the results of today's Annual General Meeting
EQ
05/19Medacta Group SA Approves Distribution
CI
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 427 M 437 M 437 M
Net income 2022 57,0 M 58,3 M 58,3 M
Net Debt 2022 115 M 117 M 117 M
P/E ratio 2022 31,5x
Yield 2022 0,67%
Capitalization 1 897 M 1 940 M 1 940 M
EV / Sales 2022 4,71x
EV / Sales 2023 4,11x
Nbr of Employees 1 341
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 94,88 €
Average target price 115,60 €
Spread / Average Target 21,8%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-32.68%2 004
ABBOTT LABORATORIES-22.37%190 883
MEDTRONIC PLC-9.83%124 341
BECTON, DICKINSON AND COMPANY4.15%73 001
HOYA CORPORATION-15.34%38 786
DEXCOM, INC.-31.91%35 882